{
  "folder": "IC-330",
  "content": "{{knowledge objective\n|Identifiant=OIC-330-02-A\n|Item_parent=Prescription and monitoring of the most common classes of medicines in adults and children, excluding anti-infectives (see item 177). Knowing the correct use of the main therapeutic classes.\n|Item_parent_short=Prescribing and monitoring the most common classes of medicines for adults and children, excluding anti-infectives (see item 177). Knowing the correct use of the main therapeutic classes\n|Rank=A\n|Title=Diuretics: mechanisms of action, indications, side-effects, drug interactions, monitoring procedures and main causes of failure.\n|Description=Knowing the mechanisms of action\n|Rubric=Management\n|Contributors=Marie Briet,Jean-Michel Halimi\n|Order=2}}\n\n\n='''Diuretics'''=\n\n== ''Three drug classes'' ==\n\n[[File:Diuretics.png|vignette|Diuretics]]\n\n*Loop diuretics (e.g. furosemide)\n*Thiazide diuretics (e.g. hydrochlorothiazide)\n*Potassium-sparing diuretics (e.g. amiloride, spironolactone)\n\n<br />\n== '''Mechanisms of action'''==\n\n===Loop diuretics===\n\n*Natriuretic effect due to inhibition of the NKCC2 co-transporter [\"Na-K-Cl cotransporter\"] at the level of the large ascending branch of Henl\u00e9.\n*Associated effects: renal loss of calcium and magnesium, renal loss of potassium and metabolic alkalosis.\n\n===Thiazide diuretics===\n\n*Natriuretic effect due to inhibition of the NCC transporter in the distal convoluted tubule.\n*Associated effects: altered dilution capacity, renal potassium loss, reduced urinary calcium excretion.\n\n===Potassium-sparing diuretics===\nTwo mechanisms of action depending on the molecule:\n\n*Inhibition of the epithelial sodium channel (eNaC) (''amiloride'')\n*Aldosterone receptor antagonist (spironolactone)\n*Associated effects: potassium sparing, metabolic acidosis\n\n=='''Indications'''==\n\n===Loop diuretics===\n\n*Edema of cardiac, renal (in particular nephrotic syndrome) or hepatic origin (usually in association with a potassium-sparing diuretic).\n*Heart failure in adults|Heart failure\n*Arterial hypertension SD-042|Arterial hypertension]] in patients with chronic renal failure when thiazide diuretics are contraindicated (particularly when creatinine clearance is < 30 ml/min).\n\n===Thiazide diuretics===\n\n*High blood pressure\n*Edema of cardiac, renal or hepatic origin (usually in combination with a potassium-sparing diuretic).\n\n===Potassium-sparing diuretics===\n\n*eNaC inhibitor (amiloride): In association with thiazide or loop diuretics, to prevent potassium depletion; ascites and oedema in cirrhotics.\n\n===Aldosterone receptor antagonist===\n\n*Hyperaldosteronism secondary to diuretic treatment or oedema.\n*Essential arterial hypertension and resistant arterial hypertension (after use of a validated triple antihypertensive therapy at the right dose and hygiene and dietary measures).\n*Stage III or IV heart failure, in association with a loop diuretic or a conversion enzyme inhibitor.\n*Adjuvant therapy for myasthenia to reduce potassium requirements.\n\n==''Adverse reactions'''==\n\n===Loop diuretics and thiazides===\n\n*Hypokalaemia, metabolic alkalosis, hyponatraemia, hyperuricaemia, volume depletion.\n*glucose intolerance, increased triglycerides\n*Immuno-allergic reaction\n*Tinnitus, deafness (loop diuretics)\n*Hypercalcaemia (thiazide diuretics), hypomagnesaemia (loop diuretics)\n\n===Potassium-sparing diuretics===\n\n*Hyperkalaemia, metabolic acidosis\n*Gynecomastia, impotence, menstrual irregularity, libido disorders (non-specific aldosterone receptor antagonists).\n*Immuno-allergic reaction\n\n==''Drug interactions'''==\n\n===With loop and thiazide diuretics===\n\n*Drugs that prolong the QT interval '''' (risk of torsade de pointes)\n*Lithium: risk of increased lithaemia\n*Non-steroidal anti-inflammatory drugs, blockers of the renin angiotensin system: risk of acute renal failure.\n\n===With potassium-sparing diuretics===\n\n*hyperkalaemic'' drugs (ciclosporin, tacrolimus, renin angiotensin system blockers, non-steroidal anti-inflammatory drugs, trimethoprim), particularly in diabetic patients and/or patients with heart failure, who are at greater risk of hyperkalaemia.\n*Lithium: risk of increased lithaemia\n*Non-steroidal anti-inflammatory drugs, renin angiotensin system blockers: risk of acute renal failure.\n\n==''Contraindications'''==\n\n===Loop diuretics===\n\n*Hypersensitivity\n*Urinary tract obstruction, hypokalaemia, hypovolaemia\n*Acute hepatitis, severe hepatocellular insufficiency (furosemide)\n*Pregnancy and breast-feeding\n\n===Potassium-sparing diuretics===\n\n*Hypersensitivity, hyperkalaemia, severe or acute renal failure, pregnancy, breast-feeding.\n\n== '''Monitoring procedures'''==\n\n*Clinical: weight, hydration status, blood pressure, orthostatic hypotension, skin fold, etc.\n*Biological: kalaemia, natraemia, creatininaemia, calcaemia in certain patients on thiazides, uric acid, etc.\n*ECG if hypo- or hyperkalaemia\n\n== '''Causes of failure'''==\n\n*Refractory oedema: severe hypoalbuminemia, heart failure, etc.\n*Hypertension: need for multiple anti-hypertensive therapies",
  "question": {
    "properties": {
      "question": {
        "title": "What is a common adverse reaction associated with potassium-sparing diuretics?",
        "description": "A list of strings",
        "type": "string"
      },
      "option_a": {
        "title": "Hyperkalaemia, metabolic acidosis",
        "description": "A possible adverse reaction associated with potassium-sparing diuretics",
        "type": "string"
      },
      "option_b": {
        "title": "Hypokalaemia, metabolic alkalosis",
        "description": "A common adverse reaction associated with loop and thiazide diuretics",
        "type": "string"
      },
      "option_c": {
        "title": "Glucose intolerance, increased triglycerides",
        "description": "A common adverse reaction associated with loop and thiazide diuretics",
        "type": "string"
      },
      "option_d": {
        "title": "Hypercalcaemia, hypomagnesaemia",
        "description": "A common adverse reaction associated with thiazide diuretics",
        "type": "string"
      },
      "correct_option": {
        "title": "Hyperkalaemia, metabolic acidosis",
        "description": "The correct answer",
        "type": "string"
      }
    },
    "required": [
      "question",
      "option_a",
      "option_b",
      "option_c",
      "option_d",
      "correct_option"
    ]
  }
}